Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: A review

References

• Gupta PC, Warnakulasuriya S. Global epidemiology of Areca nut usage. Addict Biol 2002;7:77–83.
   PubMed Web of Science ®Google Scholar
• Giri S, Idle JR, Zabriskie TM, Krausz KW, Gonzalez FJ. A metabolomic approach to the areca nut alkaloids arecoline and arecaidine in the mouse. Chem Res Toxicol 2006;19:818–27.
   PubMed Web of Science ®Google Scholar
• Norton SA. Betel: Consumption and consequences. J Am Acad Dermatol 1998;38:81–8.
   PubMed Web of Science ®Google Scholar
• De Miranda CM, Van Wyk CV, Van Der Biji P, Basson NJ. The effect of areca nut on salivary and selected oral microorganisms. Int Dent J 1996;46:350–6.
   PubMedGoogle Scholar
• Inokuchi JI, Okabe H, Yamauchi T, Nagamatzu A, Nonaka G, Nishioka I. Antihypertensive substance in seeds of Areca catechu. Life Sci 1986;38:1375–1382.
   PubMed Web of Science ®Google Scholar
• Hsu HF, Tsou TC, Chao HR, Shy CG, Kuo YT, Tsai FY, . Effects of Arecoline an adipogenesis, lipolysis and glucose uptake of adipocytes. A possible role of betel quid chewing in metabolic syndrome. Toxicol Appl Pharmacol 2010;245:370–7.
   PubMed Web of Science ®Google Scholar
• Tseng CH. Betel nut chewing and subclinical ischemic heart disease in diabetic patients. Cardiol Res Pract 2011:451–89.
   Google Scholar
• Zhang X, Reichart PA. A review of betel quid chewing, oral cancer and precancer in Mainland China. Oral Oncol 2007;43:424–30.
   PubMed Web of Science ®Google Scholar
• Canniff JP, Harvey W. The aetiology of oral sub-mucous fibrosis; the stimulation of collagen synthesis by extract of Areca nut. Int J Oral Surg 1981;10:163–7.
   PubMedGoogle Scholar
• Farnworth ER. Betel nut—Its composition, chemistry and uses. Sci New Guinea 1976;4:85–90.
   Google Scholar
• Sundqvist K, Liu Y, Nair J, Bartsch H, Arvidson K, Grafstrom RC. Cytotoxic and genotoxic of areca nut-related compounds in cultured human buccal epithelial cells. Cancer Res 1989;49:5294–8.
   PubMed Web of Science ®Google Scholar
• Asthana S, Greig NH, Holloway HW, Raffaele KC, Berardi A, Shapiro MB, . Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease. Clin Pharmacol Ther 1996; 60:276–82.
   PubMed Web of Science ®Google Scholar
• Baucher BJ, Mannan N. Metabolic effects of the consumption of Areca catechu. Addict Biol 2002;7:103–10.
   PubMed Web of Science ®Google Scholar
• Chu NS. Effects of betel chewing on the central and autonomic nervous system. J Biomed Sci 2001;8:229–36.
   PubMed Web of Science ®Google Scholar
• Dar A, Khatoon S. Behavioral and biochemical studies of dichloromethane fraction from the Areca catechu nut. Pharmacol Biochem Behav 2000;65:1–6.
   PubMed Web of Science ®Google Scholar
• Dar A, Khatoon S. Antidepressant effects of ethanol extract of Areca catechu in rodents. Phytotherapy Res 1997;11:174–6.
   Web of Science ®Google Scholar
• Pfeiffer CC, Jenney EH. The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain. Ann NY Acad Sci 1957;66:753–64.
   PubMed Web of Science ®Google Scholar
• Moltzen E, Bjornholm B. Medicinal chemistry of muscarinic agonists: Developments since 1990. Drugs Future 1995;20:37–54.
   Google Scholar
• Shannon HE, Rasmussen K, Bymaster FP, Hait JC, Peters SC, Swedberg MD, . Xanomeline, an M(1) M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like effect in rats and mice. Schizophr Res 2000;42:249–59.
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Allen JS, Otto C, Tiobech J, Nero K. Effects of chewing betel nut (Areca catechu) on the symptoms of people with schizophrenia in Palau, Micronesia. Br J Psychiatry 2000;177:174–8.
   PubMed Web of Science ®Google Scholar
• Ysaol J, Chilton JI, Callaghan P. A survey of betel nut chewing in Palau. J Micronesian Stud 1996;4:244–55.
   Google Scholar
• Futterman A, Lyman A. Palau Substance Abuse Needs Assessment (SANA). Palau: Ministry of Health; 1998.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd edition (DSM-III). Washington DC: American Psychiatric Association; 1980.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV). Washington DC: American Psychiatric Association; 1994.
   Google Scholar
• Kay SR, Opler RA, Fiszbein A. Positive and negative syndrome scale (PANSS): Manual. New York: Multi-Health Systems; 1992.
   Google Scholar
• Chouinard G, Ros-Chouinard A. Manual: Extra-pyramidal Symptom Rating Scale (ESRS). Montreal: Department of Psychiatry, McGill University; 1979.
   Google Scholar
• Sullivan RJ, Andres S, Otto C, Miles W, Kydd R. The effects of an indigenous muscarinic drug, betel nut (Areca catechu), on the symptoms of schizophrenia: A longitudinal study in Palau, Micronesia. Am J Psychiatry 2007;164:670–3.
   PubMed Web of Science ®Google Scholar
• Ware J Jr, Kosinski M, Keller SD. A 12-item Short-Form Health Survey: Construction of scale and preliminary tests of reliability and validity. Med Care 1996;34:220–33.
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbaurne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. Washington DC: Department of Health, Education and Welfare; 1976.
   Google Scholar
• Simpson GM, Angus JWS. A rating scale for extra-pyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11–9.
   PubMedGoogle Scholar
• Bales A, Peterson MJ, Ojha S, Upadhaya K, Adhikari B, Barrett B. Associations between betel nut (Areca catechu) and symptoms of schizophrenia among patients in Nepal: A longitudinal study. Psychiatry Res 2009;169:203–11.
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, . The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic interview for DSM IV and ICD-10. J Clin Psychiatry 1998;59:22–33.
   PubMed Web of Science ®Google Scholar
• Kay SR, Opler RA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): Rationale and standardization. Br J Psychiatry 1989;7:59–67.
   Google Scholar
• Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-Evaluation Scale. Eur Neuropsychopharmacol 1997;7:57–70.
   PubMed Web of Science ®Google Scholar
• Andreasen NC. Schizophrenia: The fundamental questions. Brain Res 2000;31:106–12.
   Web of Science ®Google Scholar
• Scarr E, Dean B. Role of the cholinergic system in the pathology and treatment of schizophrenia. Expert Rev Neurother 2009;9:73–86.
   PubMed Web of Science ®Google Scholar
• Harrison PJ. The neuropathological effects of antipsychotic drugs. Schizophr Res 1999;40:87–99.
   PubMed Web of Science ®Google Scholar
• Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: A study of Brodmann's areas 8, 9, 10 and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001;158:918–25.
   PubMed Web of Science ®Google Scholar
• Tandon R. Cholinergic aspects of schizophrenia. Br J Psychiatry 1999;174:7–11.
   Web of Science ®Google Scholar
• Brown TA, Zador AM. Hippocampus. Shepherd GM. The synaptic organization of the brain. New York: Oxford University Press; 1990. 346–88.
   Google Scholar
• Pisani A, Bernardi G, Ding J, Surmeier DJ. Re-emergence of striatal cholinergic interneurons in movement disorders. Trend Neurosci 2007;20:545–53.
   Google Scholar
• Hasselmo ME. The role of acetylcholine in learning and memory. Curr Opin Neurobiol 2006; 16:710–5.
   PubMed Web of Science ®Google Scholar
• Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease—The pivotal role of brain M1 receptors. Neurodegener Dis 2008;5:237–40.
   PubMed Web of Science ®Google Scholar
• Wess J, Eglen RM, Gantan D. Muscarinic acetylcholine receptors: Mutant mice provide new insights for drug development. Nat Rev Drug Discov 2007;6:721–33.
   PubMed Web of Science ®Google Scholar
• Owen F, Cross AJ, Crow TJ, Lofthouse R, Poulter M. Neurotransmitter receptors in brain in Schizophrenia. Acta Psychiatr Scand Suppl 1981;291:20–8.
   PubMedGoogle Scholar
• Watanabe S, Nishikawa T, Takashima M, Toru M. Increased muscarinic cholinergic receptors in prefrontal cortex of medicated schizophrenics. Life Sci 1983;33:2187–96.
   PubMed Web of Science ®Google Scholar
• Bennet JP Jr, Enna JJ, Bylund DB, Jillin JC, Wyatt RJ, Snyder SH. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 1979;36:927–34.
   PubMed Web of Science ®Google Scholar
• Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DN. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1996; 1:54–8.
   PubMed Web of Science ®Google Scholar
• Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptors binding in subjects with schizophrenia: A study of the human hippocampal formation. Biol Psychiatry 2000;48:381–8.
   PubMed Web of Science ®Google Scholar
• Newell KA, Zavitsanou K, Jew SK, Huang XF. Alteration of muscarinic and GABA receptor binding in the posterior cingulated cortex in schizophrenia. Prog Neuripsychopharmacol Biol Psychiatry 2007;31:225–33.
   PubMed Web of Science ®Google Scholar
• Crook JM, Dean B, Pavey G, Copolov D. The binding of [3H] AFDX 384 is reduced in the caudate-putamen of subject with schizophrenia. Life Sci 1999;64:1761–71.
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. Possible changes in striatal and limbic cholinergic systems in schizophrenia. Arch Gen Psychiatry 1977;34:1319–23.
   PubMed Web of Science ®Google Scholar
• Bird ED, Spokes EG, Barnes J, MacKay AV, Iversen LL, Shepherd M. Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyltransferase activity in schizophrenia and related psychosis. Lancet 1977;2:1157–8.
   PubMed Web of Science ®Google Scholar
• Karson CN, Casanova MF, Kleinman JE, Griffin WS. Choline acetyltransferase in schizophrenia. Am J Psychiatry 1993;15:454–9.
   Google Scholar
• Bustillo JR, Rowland LM, Lauriello J, Petropoulos H, Hammond R, Hart B, . High choline concentrations in the caudate nucleus in antipsychotic naïve patients with schizophrenia. Am J Psychiatry 2002;159:130–3.
   PubMed Web of Science ®Google Scholar
• Theberge J, Al Semaan Y, Drost DJ, Malla AK, Neufeld RW, Bartha R, . Duration of untreated psychosis vs N-acetylaspartate and choline in first episode schizophrenia: A 1 H magnetic resonance spectroscopy study at 4.0 Tesla. Psychiatry Res 2004;131:107–14.
   PubMed Web of Science ®Google Scholar
• Tandon R, Man RA, Eismer WH, Coppard N. Effects of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Res 1990;31:235–41.
   PubMed Web of Science ®Google Scholar
• Perry PJ, Wilding DC, Juhl RP. Anticholinergic Psychosis. Am J Hosp Pharm 1978;35:725–8.
   PubMedGoogle Scholar
• Wilkinson JA. Side effects of transdermal scopolamine. J Emerg Med 1987;5:389–92.
   PubMedGoogle Scholar
• Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, . Effects of xanomeline, a selective muscarinic receptors agonist, on cognitive function and behavioural symptoms in Alzheimer disease. Arch Neurol 1997;54:465–73.
   PubMed Web of Science ®Google Scholar
• Shekhar A, Potter WZ, Lienemann J, Sundblad K, Lightfoot J, Herrera J, . Efficact of xanomeline, a selective muscarinic agonist, in treating schizophrenia: A double-blind, placebo controlled study. Waikoloa, HI, USA: ACNP 40 Annual Meeting; 2001. Abstract 13532.
   Google Scholar
• Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 1989;46:745–53.
   PubMed Web of Science ®Google Scholar
• Andersen MB, Fink-Jensen A, Peacock L, Gerlach J, Bymaster FP, Lundbaek JA, . The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology 2003;28:1168–75.
   PubMed Web of Science ®Google Scholar
• Bridges TM, LeBois EP, Hopins CR, Wood MR, Jones PJ, Conn PJ, . The antipsychotic potential of muscarinic allosteric modulation. Drug News Perspect 2010;23:229–40.
   PubMedGoogle Scholar
• Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Ward JS, Caligaro DO, . Potential role of muscarinic receptors in schizophrenia. Life Sci 1999;64:527–34.
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Felder C, Ahmed S, Mckinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 2002;1:163–81.
   PubMedGoogle Scholar
• Clader JW, Wang Y. Muscarinic receptor agonists in the treatment of Alzheimer's disease. Curr Pharm Des 2005;11:3353–61.
   PubMed Web of Science ®Google Scholar
• Craft RM. Sex differences in drug and non drug-induced analgesia. Life Sci 2003;72:2675–88.
   PubMed Web of Science ®Google Scholar
• Hyman SE, Fenton WS. Medicine: What are the right targets for psychopharmacology? Science 2003;299:350–1.
   PubMed Web of Science ®Google Scholar
• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321–30.
   PubMed Web of Science ®Google Scholar
• Weickert TW, Goldberg TE. First and second generation antipsychotic medication and cognitive processing in schizophrenia. Curr Psychiatry Rep 2005;7:304–10.
   PubMedGoogle Scholar
• Peuskens J, Demily C, Thibout F. Treatment of cognitive dysfunction in schizophrenia. Clin Ther 2005;27:25–37.
   PubMed Web of Science ®Google Scholar
• Mancama D, Arranz MJ, Landau S, Kerwin RW. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003;119:2–6.
   Google Scholar
• Liao DL, Hong CM, Chen HM, Chen YE, Lee SM, Chang CY, . Association of muscarinic M1 receptor genetic polymorphisms with psychiatry symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 2003;48:72–6.
   PubMed Web of Science ®Google Scholar
• Sarter M, Bruno JP. Cognitive function of cortical acetylcholine: Toward a unifying hypothesis. Brain Res Brain Res Rev 1997;23:28–46.
   PubMed Web of Science ®Google Scholar
• Nahas Z, George MS, Horner MD. Augmenting atypical antipsychotics with a cognitive enhancer (donapezil) improves regional brain activity in schizophrenia patients: A pilot double blind placebo controlled blood fMRI study. Neurocase 2003;9:274–82.
   PubMed Web of Science ®Google Scholar
• Scherbert MH, Young KA, Hicks PB. Galantamine improves cognitions in schizophrenic patients stabilized on risperidone. Biol Psychiatry 2006;60:530–3.
   PubMed Web of Science ®Google Scholar
• White KE, Cumnings JL. Schizophrenia and Alzheimer's disease: Clinical and pathophysiologic analogies. Compr Psychiatry 1996;37:188–95.
   PubMed Web of Science ®Google Scholar
• Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev 2003;9:159–86.
   PubMedGoogle Scholar
• Yang YK, Nelson L, Kamaraju L, Wilson W, McEvoy JP. Nicotine decreases Bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. Neuropsychopharmacology 2002;27:684–6.
   PubMed Web of Science ®Google Scholar
• Moreira EL, Rial D, Duarte FS, de Carvalho CR, Horst H, Pizzolatti MG, . Central nervous system activity of proanthocyanidin-rich fraction obtained from croton celtidifolius in rats. J Pharm Pharmacol 2010;62:1061–8.
   PubMed Web of Science ®Google Scholar